Published in Am J Cardiol on April 21, 1982
Withdrawal of Medication in Recovered DCM (WrecEF) | NCT02770443
Captopril in heart failure. A double blind controlled trial. Br Heart J (1984) 2.85
Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J (1985) 2.74
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J (1983) 1.07
Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J (1994) 0.86
Beneficial effects of captopril in left ventricular failure in patients with myocardial infarction. Br J Clin Pharmacol (1982) 0.75
Sponsorship, authorship, and accountability. Lancet (2001) 7.10
Sponsorship, authorship, and accountability. N Engl J Med (2001) 6.20
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 6.01
Sponsorship, authorship and accountability. CMAJ (2001) 5.86
Unsatisfactory redefinition of myocardial infarction. Lancet (2001) 2.89
Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med (1974) 2.60
Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A (1982) 2.52
Management of raised blood pressure in New Zealand. N Z Med J (1993) 2.48
The Elag-Koln automatic blood pressure recorder. A clinical appraisal. Br Heart J (1977) 2.34
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation (1998) 2.17
Management of raised blood pressure. N Z Med J (1994) 2.03
Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet (1985) 1.95
Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med (1989) 1.91
Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen. Lancet (1973) 1.89
The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol (1977) 1.86
Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) (1997) 1.73
Cardiogenic shock treated with infusion of dextrose solution. Am Heart J (1967) 1.69
Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects. Br Med J (1977) 1.68
Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke (1991) 1.61
Diagnostic index for premyxoedema. Lancet (1973) 1.61
Clinical evaluation of perhexiline maleate in patients with angina pectoris. Br Med J (1971) 1.60
Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. Br Heart J (1976) 1.59
Liquorice toxicity and the renin-angiotensin-aldosterone axis in man. Br Med J (1977) 1.56
Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study. J Hum Hypertens (1989) 1.55
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol (2001) 1.54
Cough with angiotensin converting-enzyme inhibitors. N Z Med J (1987) 1.48
Blood-pressure response to moderate sodium restriction and to potassium supplementation in mild essential hypertension. Lancet (1984) 1.48
Hypertension--still an important cause of heart failure? J Hum Hypertens (2005) 1.46
Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf) (1996) 1.45
The nature and prognosis of thyrotoxic heart disease. Q J Med (1985) 1.43
The management of mildly raised blood pressure in New Zealand: an alternative view. N Z Med J (1996) 1.42
A neural mechanism for sudden death after myocardial infarction. Clin Auton Res (2003) 1.41
Congenital long QT syndrome in adults. N Z Med J (1989) 1.39
Sulindac and cough induced by converting enzyme inhibitors. Lancet (1987) 1.38
Calorie-restricted weight reduction, blood pressure, and atrial natriuretic peptides. Nutrition (1993) 1.38
Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab (1993) 1.38
Treatment of severe orthostatic hypotension with the somatostatin analogue octreotide. Aust N Z J Med (1990) 1.37
The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun (1995) 1.33
Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab (1994) 1.29
High concentrations of thyroid-stimulating hormone in untreated glucocorticoid deficiency: indication of primary hypothyroidism? Br Med J (Clin Res Ed) (1982) 1.28
Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure. Lancet (1981) 1.26
Decrease in cardiac output and muscle sympathetic activity during vasovagal syncope. Am J Physiol Heart Circ Physiol (2002) 1.24
Sponsorship, authorship, and accountability. JAMA (2001) 1.22
Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab (1993) 1.21
Hyponatremic-hypertensive syndrome with renal ischemia: an underrecognized disorder. Hypertension (1999) 1.20
Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J (1993) 1.19
Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol (1985) 1.18
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease. Br Heart J (1985) 1.18
Haemodynamic effects of atrial peptide infusion in heart failure. Lancet (1986) 1.16
Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ (1992) 1.15
Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab (1986) 1.14
Patients presenting with Addison's disease need not be pigmented. Postgrad Med J (1982) 1.13
Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2007) 1.13
An unusual cause of hyperinsulinaemic hypoglycaemia syndrome. Diabet Med (2003) 1.12
Atrial function following cardioversion. Am Heart J (1967) 1.12
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation (1999) 1.12
Natriuretic hormones. Endocrinol Metab Clin North Am (1995) 1.12
High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol (1995) 1.11
Autonomic control of vasovagal syncope. Am J Physiol (1998) 1.11
The haemodynamic, histopathological and hormonal features of alcoholic cardiac beriberi. Q J Med (1981) 1.10
Stroke subtypes among Chinese living in Hong Kong: the Shatin Stroke Registry. Neurology (1992) 1.09
Left atrial function after electrical conversion to sinus rhythm. Br Heart J (1968) 1.09
Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) (1980) 1.09
Clinical features of non-tuberculous constrictive pericarditis. Thorax (1974) 1.07
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J (1983) 1.07
New government, same narrow vision. Health authorities in New Zealand have spin doctors to produce good news. BMJ (1998) 1.07
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int (2000) 1.06